You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Illumina thinks the next-generation sequencing cancer testing market will grow to $75 billion over the next 15 years, driven by screening.
The company recently had a second pre-submission with FDA and expects to begin a prospective trial of its test in the second half of this year.
Dogs age more rapidly in their early years but then age more slowly later on, a DNA methylome analysis found, changing how dogs' ages are translated to human ages.
Investigators identified dozens of Alzheimer's-related epigenetic signatures based on cytosine methylation and other profiles in Alzheimer's-related cell lines and patient samples.
The Methyl-HiC assay, which combines epigenetic and genome structure analyses, comes from a lab with a history of commercializing tests.
The approach, called cfMeDIP-seq, could distinguish early-stage pancreatic cancer from healthy controls and differentiate several types of cancer.
Stanford University's Michael Snyder found that methylome shifts preceded spikes in his blood glucose levels, suggesting profiling could detect disease.
The team uncovered more than 200 sites in the human genome that were differentially methylated based on parent of origin, including areas linked to disease.
The researchers said the method can help subtype and identify rare cells with clinical implications in neurodevelopment and cancer.
In Nature this week: genome-editing to treat hearing loss in mice, juvenile myelomonocytic leukemia subgroups, and more.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.